Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bladder including urinary frequency, urgency or urgency incontinence.


Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite.

The efficacy of fesoterodine has been assessed in two phase III 12-week trials1,2 in patients with overactive bladder syndrome.

Patients were randomised to placebo, 4mg fesoterodine or 8mg fesoterodine once daily for 12 weeks. The primary efficacy end point was the change in the number of micturitions per 24 hours. Co-primary end points were the change in the number of urgency urinary incontinence (UUI)episodes per 24 hours and the treatment response.

The trials showed statistically significant and clinically relevant improvements in primary and co-primary end points in patients taking 4mg fesoterodine and 8mg fesoterodine compared to placebo.

View Toviaz drug record

1. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007: 52; 1204–12.
2. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007: 178; 2488–94.

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more